Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

#4501

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Aim(s): To explore the efficacy and safety of surufatinib in unresectable or metastatic NET G3.

Materials and methods: This is a national multi-centre, retrospective study analysing the efficacy and safety of surufatinib-based treatment in NET G3 patients (pts). Eligible pts had unresectable or metastatic NET with Ki-67 > 20%. The primary endpoint was progression-free survival (PFS).

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,